With great pleasure, we welcome you to the symposium “Breast Cancer Risk and Prognostication: Germline and Tumor Genetics” organized online on 23rd and 24th Feb 2021 for celebrating the closure and progress of the EU Horizon 2020 projects B-CAST and BRIDGES.
Currently, primary breast cancer prevention is only offered to women at a high risk, e.g. BRCA1- or BRCA2-mutation carriers. National population breast cancer screening programs focus typically on women above 50 years of age. B-CAST and BRIDGES are aiming at better understanding of the genetic and risk factor that lead to specific of breast cancer subtypes with subsequent prognosis. With this better understanding, early detection and prevention of breast cancer can be improved for all women. In this closing symposium, we will share the latest (preliminary) results from these two EU Horizon 2020 projects. The symposium is open to all scientists, other healthcare professionals and patient advocates are also welcome.
There are also two closed attendance satellite meetings 17:00-18:00 CET.
Organisers: Prof Dr Marjanka Schmidt (Lead PI B-CAST) & Prof Dr Peter Devilee (Lead PI BRIDGES)
Registration: Please register here latest by 16th February 2021. A link for the online zoom meeting will be shared with participants upon registration.
Talks of 15 minutes followed by 5 minutes Q&A
14:00-14:10: Welcome and introduction (Marjanka Schmidt, Netherlands Cancer Institute)
14:10-14:15: Tumor Panel Sequencing 10,000 tumors. A behind the scene video by CNAG.
14:15-14:35: Tumor genetic profiles: associations with tumor subtypes and outcome (Sander Canisius, Netherlands Cancer Institute)
14:35-14:55: Data for AI Models for Scoring of IHC Markers in B-CAST: Opportunities and Challenges (Mustapha Abubakar, National Cancer Institute/NIH)
14:55-15:15: Automated calling of tissue infiltrated lymphocytes (Aaron Bernstein, Cambridge University and National Cancer Institute)
15:15-15:35: Do we need subtype specific risk models? (Audrey Jung, German Cancer Research Center, DKFZ))
15:35-15:55: Incorporating PR status into the PREDICT breast prognostication model (Isabelle Grootes, University of Cambridge)
15:55-16:00 Closure (Marjanka Schmidt)
Closed Meeting: Focused discussion with the studies who have provided tumor samples for B-CAST panel sequencing (participation is by invitation only)
Talks of 15 minutes followed by 5 minutes Q&A
14:00-14:10: Welcome and introduction (Peter Devilee, Leiden University Medical Center)
14:10-14:30: Elucidating functional impact and cancer risk associated with genetic variants in PALB2 and CHEK2 (Rick Boonen, Leiden University Medical Center)
14:30-14:50: Naturally occurring alternative splicing, minigene-based analysis, and clinical classification of spliceogenic variants (Miguel de la Hoya, Molecular Oncology Laboratory of Hospital Clínico San Carlos)
14:50-15:10: Psycho-oncological study on risk perception (Anne Brédart, Institute Curie)
15:10-15:30: Clinical translation of comprehensive risk prediction (Rita Schmutzler, University of Cologne)
15:30-15:40: Break
15:40-16:20: BOADICEA: further updates to the breast cancer risk model and validation studies in independent prospective cohorts (Andrew Lee and Xin Yang, Cambridge University)
16:20-16:35: Personalising breast cancer prevention - bridging the gap between research and policy (Sowmiya Moorthie, PHG)
16:35-16:45 Closure (Peter Devilee)
Closed meeting: B-CAST Final Project Review Meeting with EU Project Officer, Dr Ioannis VOULDIS
These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633784 and 634935
